Foreign pharma companies restructuring Russian subsidiaries face licensing and registration risks. A practical guide for in-house counsel. Make an enquiry.
Unlike many European jurisdictions, which converged on a relatively unified insolvency and restructuring framework following EU Directives, Russian corporate law maintains a distinct taxonomy of reorganisation forms — each with its own procedural sequence, regulatory notification obligations, and, for pharmaceutical companies specifically, implications for the continuity of drug registration certificates and manufacturing licences. For in-house counsel at a foreign pharmaceutical group with a Russian subsidiary, understanding which reorganisation option achieves the group's commercial objective — without triggering a gap in regulatory authorisation — is the practical starting point.
The following checklist should be completed before any reorganisation structure is submitted to the board of the Russian entity or its foreign parent for approval.
For in-house counsel managing the pre-reorganisation audit at the Russian subsidiary level, early engagement with local counsel is advisable before the board memorandum is finalised — make an enquiry: info@vetrovpartners.com |
Russian corporate legislation provides for five forms of reorganisation: merger (sliyanie), acquisition (prisoedinenie), division (razdelenie), spin-off (vydelenie), and conversion (preobrazovanie). Each is available to both OOOs and AOs, though the procedural mechanics differ between the two corporate forms.
For a foreign pharmaceutical group, the most frequently relevant options are the following. Acquisition — where a Russian subsidiary absorbs, or is absorbed into, another Russian group entity — is commonly used to consolidate multiple Russian legal entities into a single operating subsidiary. The acquiring entity becomes the universal legal successor of the absorbed company, which in principle preserves contractual rights and obligations. Division creates two or more entirely new legal entities from the predecessor, which ceases to exist; this is relatively uncommon in pharmaceutical structures because regulatory authorisations are extinguished with the predecessor and must be reissued for each successor. Spin-off allows a parent entity to remain in existence while transferring defined assets, rights, and liabilities to a newly created subsidiary — a useful mechanism where a foreign group wishes to separate a manufacturing function from a distribution function within its Russian structure. Conversion changes the corporate form of the entity without changing its legal identity, and is the least disruptive option from a regulatory continuity perspective.
For the pharmaceuticals sector specifically, the choice between these forms is heavily influenced by the status of drug registration certificates. Under the applicable EAEU regulatory framework, DRCs are issued to a named legal entity. In a merger or acquisition resulting in universal succession, the successor entity must, as a general rule, apply to transfer the DRCs into its own name — a process that involves Roszdravnadzor and carries its own timeline. Conversion is the principal exception: because the entity's legal identity is preserved, DRCs typically remain valid and do not require reissuance.
Note: The DRC transfer timeline under Roszdravnadzor practice is not automatic and, in practice, commonly extends to several months. A pharmaceutical company that does not initiate the DRC transfer application at the earliest procedural opportunity may face a period during which the relevant product cannot lawfully be placed on the Russian market. This risk should be factored into the reorganisation timeline from the outset.
Once the reorganisation form is selected and the relevant corporate decision is taken, Russian law requires the reorganising entity to notify both creditors and state authorities within defined timeframes.
The EGRUL notification is filed with the Federal Tax Service (FTS) within three business days of the corporate decision. From that notification, a mandatory two-month creditor objection period runs. During this period, any creditor of the reorganising entity may demand early repayment of debts or the provision of additional security. For pharmaceutical companies with active supply and distribution contracts, the management of creditor notification and any resulting demands requires active coordination between the legal, finance, and operations functions.
In parallel, and separately from the corporate law notification regime, Roszdravnadzor should be informed of the planned reorganisation. While Russian corporate legislation does not impose a standalone obligation on Roszdravnadzor notification as a condition of reorganisation registration, the agency's administrative practice means that post-registration contact — particularly regarding DRC transfer applications — proceeds more smoothly where the regulator has been engaged during the process rather than after the fact.
For foreign parent companies subject to EAEU pharmaceutical regulations, the EEC (Eurasian Economic Commission) notification requirements in respect of authorised pharmaceutical products should be reviewed in parallel with the Russian domestic notification process, as they operate on separate tracks.
Firms advising clients on Russian subsidiary governance will often need a confirmed Russian counsel relationship before creditor notification deadlines and regulatory filings create timing constraints — make an enquiry: info@vetrovpartners.com |
Following the creditor objection period, the final stage of the reorganisation is registration with the FTS. The registration package includes the transfer deed (peredatochny akt) or separation balance sheet (razdelitelny balans), depending on the reorganisation form, together with confirmation that creditor notification has been completed and that no outstanding creditor demands remain unsatisfied or unresolved.
The timeline from corporate decision to completed FTS registration, in the absence of creditor demands and assuming complete documentation, typically extends to three to four months for straightforward merger and acquisition structures. Division and spin-off structures — which involve the creation of new legal entities — carry additional corporate documentation requirements and commonly take longer in practice.
For pharmaceutical companies, the period between FTS registration of the reorganisation and the completion of DRC transfers into the successor entity's name represents the principal operational risk window. During this interval, the managing counsel should coordinate with Roszdravnadzor to ensure that the DRC transfer application is processed concurrently with, or immediately following, the reorganisation registration — and that the applicable GMP compliance status of the successor entity is confirmed without interruption.
The firm has acted for foreign pharmaceutical groups in reorganisation matters within the Restructuring & Insolvency and Corporate Governance practices. A record of representative matters is available at Matters.
The conclusion of the reorganisation process does not mark the end of the in-house counsel's workstream. A successor entity created by merger, acquisition, or spin-off will typically require an updated charter, a fresh board or director appointment resolution, updated signatory authority documentation, and — for pharmaceutical companies — an updated set of internal quality system documents referencing the successor entity's details.
Where the reorganisation involved the absorption of a Russian entity previously held by a different foreign shareholder, or where the foreign parent itself has undergone structural change above the Russian subsidiary level, the shareholder register update and foreign ownership notification obligations to the FTS should be completed promptly. Delay in updating the EGRUL record can complicate subsequent regulatory filings and licensing interactions.
For more detailed analysis of the legislative framework governing Russian corporate reorganisations, see Legislative Amendments Affecting Reorganisation and Anatomy of Reorganisation Options Under Russian Law.
The regulatory complexity of post-reorganisation pharmaceutical governance — particularly where multiple DRCs are involved across different product categories — makes this final stage a material risk area that benefits from structured legal oversight rather than routine compliance management.
Q: How long does a reorganisation typically take for a pharmaceutical company in Russia?
A: The timeline depends primarily on the reorganisation form chosen and whether any creditors exercise their right to demand early repayment during the mandatory two-month creditor objection period. For a straightforward merger or acquisition between two Russian group entities with no contested creditor demands, the period from corporate decision to completed FTS registration commonly extends to three to four months. Where a spin-off is chosen — requiring the creation of a new legal entity and preparation of a separation balance sheet — the process typically takes longer. In pharmaceutical structures, the DRC transfer process with Roszdravnadzor runs separately and should be treated as an additional workstream with its own timeline, which can add several months to the period before full operational normalisation of the successor entity.
Q: What documents does a foreign parent company need to provide for a Russian subsidiary reorganisation?
A: The Russian reorganisation process is conducted at the level of the Russian legal entity, but the foreign parent is typically required to provide: a corporate authorisation document confirming the parent's approval of the reorganisation (board resolution, shareholder resolution, or equivalent under the law of the parent's home jurisdiction), translated into Russian and apostilled or legalised as required; an updated extract from the foreign company register confirming the parent's continued legal existence and current corporate details; and, where the reorganisation involves a change in the structure of foreign ownership of the Russian entity, any additional documentation required under Russian foreign investment notification rules. The precise document set will depend on the corporate form of the Russian entity and the structure of the transaction.
Q: What happens to a drug registration certificate if the Russian entity is reorganised?
A: The answer depends on the reorganisation form. On conversion — where only the corporate form changes but the legal entity's identity is preserved — DRCs are generally unaffected and do not require reissuance. On merger, acquisition, or spin-off, the DRCs held by the predecessor or transferring entity must, as a general rule, be transferred into the name of the successor entity through a formal application to Roszdravnadzor. This transfer is not automatic and requires supporting documentation confirming the reorganisation. Until the transfer is completed, the successor entity's ability to lawfully place the relevant products on the Russian market may be affected. The practical consequence is that DRC transfer management should be treated as a parallel and time-critical workstream within the overall reorganisation project.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry